Concepedia

Author

Brian I. Rini

Cleveland ClinicORCID

Also Known As

B I Rini, B RINI, B Rini, B. I. Rini, B. Rini, B.I. Rini, BRIAN I. RINI, Brian I Rini, Brian I. Rini, Brian Ignatius Rini

1.3K

Publications

76.9K

Citations

122

H-Index

181

Concepts

All Affiliations

Cleveland ClinicMemorial Sloan Kettering Cancer CenterDana-Farber Cancer InstituteInstitut Gustave RoussyBeth Israel Deaconess Medical Center
BI

About

Brian I. Rini is an author at Cleveland Clinic specializing in medicine, oncology, and urology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

71

272

27.3K

2

Health Sciences

25

53

2.3K

3

Public Health

6

6

1.9K

4

Education

2

2

110

5

Natural Sciences

1

1

154

Brian I. Rini

×

468

Publications

65K

Citations

111

H-Index

YearCitations

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera,

New England Journal of Medicine

2018

4.5K

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus,

New England Journal of Medicine

2019

3.3K

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen,

New England Journal of Medicine

2019

2.5K

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan,

Journal of Clinical Oncology

2009

2.1K

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Brian I. Rini, Bernard Escudier, Piotr Tomczak,

The Lancet

2011

1.8K

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah,

The Lancet

2020

1.8K

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman,

Journal of Clinical Oncology

2005

1.6K

Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, Brian I. Rini, Ronald M. Bukowski,

JAMA

2006

1.2K

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F. McDermott, Mahrukh Huseni, Michael B. Atkins,

Nature Medicine

2018

1.2K

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Bernard Escudier, Thomas Powles,

New England Journal of Medicine

2015

1.2K

Page 1